

AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 9: TRAINING IN VASCULAR MEDICINE

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Mark A. Creager (Chair)	Brigham & Women's Hospital, Cardiovascular Division—Professor of Medicine, Cardiology	<ul style="list-style-type: none"> • Aastrom Biosciences • AstraZeneca* • Baxter Health Care • Itamar* • Novartis • Takeda Pharmaceuticals 	None	None	<ul style="list-style-type: none"> • Medtronics† 	<ul style="list-style-type: none"> • ABVM† • AHA† • SVM† 	None
Heather L. Gornik	Cleveland Clinic Foundation Cardiovascular Medicine—Medical Director, Noninvasive Vascular Laboratory; Staff Physician, Vascular Medicine	<ul style="list-style-type: none"> • IAME* • Northwestern University 	None	<ul style="list-style-type: none"> • Zin Medical 	<ul style="list-style-type: none"> • AstraZeneca • Theravasc 	<ul style="list-style-type: none"> • AHA† • AstraZeneca • FMDSA† • IAC-VL • IAME* • Summit Doppler Systems† • SVM† • VDF† 	None
Bruce H. Gray	University of South Carolina School of Medicine/Greenville—Professor of Surgery/Vascular Medicine; Upstate Vascular Specialists—Vascular Medicine Specialist	<ul style="list-style-type: none"> • Abbott† • Cook† 	None	None	<ul style="list-style-type: none"> • Abbott† 	<ul style="list-style-type: none"> • Gore • Medtronic 	None
Naomi M. Hamburg	Boston Medical Center Cardiovascular Medicine—Associate Professor of Medicine	<ul style="list-style-type: none"> • Pfizer • Welchs 	None	None	<ul style="list-style-type: none"> • Everest Genomics* • Fukuda Denshi • Hersheys* • NIH* • Unex* 	<ul style="list-style-type: none"> • Acceleron Pharma* • AHA • ASE • IAC-VL • SVM 	None
Emile R. Mohler, III	University of Pennsylvania Health System—Professor of Medicine	<ul style="list-style-type: none"> • Clarus Pharmaceuticals • GlaxoSmithKline • Merck • Roche • Takeda 	None	<ul style="list-style-type: none"> • Cytovas† 	<ul style="list-style-type: none"> • GlaxoSmithKline* 	<ul style="list-style-type: none"> • NIH* 	None

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
		Pharmaceuticals • UpToDate					
Christopher J. White	The Ochsner Clinical School, University of Queensland—Professor and Chairman of Medicine	• Baxter BioSurgery† • Gardia • Neovasc	None	None	• St. Jude Medical	• ACE† • NCDR-CARE Registry† • NCDR PVD† • Neovasc • SCAI† • St. Jude Medical • Surmodics	None
William Iobst	The Commonwealth Medical College, Vice Dean and Vice President for Academic and Clinical Affairs; <i>Former employment during writing effort:</i> American Board of Internal Medicine—Vice President, Academic Affairs	None	None	None	None	• ABIM*	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$10,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

ABIM = American Board of Internal Medicine; ABVM = American Board of Vascular Medicine; ACE = American Council on Exercise; AHA = American Heart Association; ASE = American Society of Echocardiography; FMDSA = Fibromuscular Dysplasia Society of America; IAC-VL = Intersocietal Accreditation Commission-Vascular Laboratories; IAME = Institute for Advanced Medical Education; NCDR-CARE = National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy Procedures; NCDR-PVD = National Cardiovascular Data Registry-Peripheral Vascular Disease; NIH = National Institutes of Health; SCAI = Society for Cardiovascular Angiography and Interventions; SVM = Society for Vascular Medicine; VDF = Vascular Disease Foundation.